An interventional study of Krill oil and Lean and fatty fish in Healthy, sponsored by Oslo Metropolitan University. Completed. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-22.
Sponsored by Oslo Metropolitan University · Not applicable, Interventional, and Prevention
Intake of omega-3 (n-3) polyunsaturated fatty acids (PUFAs) from fish oil and fish are associated with significant health benefits in risk of cardiovascular disease. However, both lean and fatty fish have been shown to have beneficial effects suggesting that not all effects are mediated by n-3 PUFAs. Krill oil is an n-3 PUFA supplement on the marked. The n-3 PUFAs from krill oil is in the form of phospholipids, and these fatty acids may be more readily and effectively absorbed after ingestion than n-3 PUFAs in the form of triacylglycerols from fish oil. Fish also contain many other potential health components than n-3 PUFAs such as taurine and vitamin D, iodine, selenium and more unspecified components such as bioactive peptides which can mediate the health beneficial effects observed after intake of fish.
The present study aims to elucidate the cardiovascular health beneficial effects after consumption of fish (lean and fatty) and krill oil, with regard to effects on plasma lipids and other markers of cardiovascular health such as inflammatory, haemostatic and endothelial dysfunction markers. The investigators will perform whole genome transcriptome analyses in peripheral blood mononuclear cells (PBMCs) in order to further understand the cardiovascular health benefits and elucidate the mechanisms of action.
Oslo Metropolitan University is the lead sponsor of 64 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Krill oil capsules. 4 g/day encapsulated krill oil (Rimfrost Sublime) corresponding to \~900 mg/day EPA + DHA + DPA for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
Dietary Supplement: Krill oil
Lean and fatty fish. Three weekly test-meals, containing two meals of fatty fish and one meal of lean fish for 8 weeks corresponding to \~900 mg/day EPA + DHA + DPA.
Other: Lean and fatty fish
Placebo capsules. 4 g/day encapsulated high oleic sunflower oil (HOSO) for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
Dietary Supplement: Placebo capsules
The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
Also known as: Rimfrost Sublime
The fish group will be open labeled.
The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
Fasting triglycerides
Time frame: 8 weeks
Circulating inflammatory markers
Such as TNFalpha and IL-6
Time frame: 8 weeks
Gene expression of inflammatory markers and genes in lipid metabolism
Measured with RT-qPCR
Time frame: 8 weeks
Plasmamlipids
Such as total- LDL- and HDL-cholesterol
Time frame: 8 weeks
Lipoprotein subclasses
Time frame: 8 weeks
Plasma fatty acid composition
Time frame: 8 weeks
Blood pressure
Time frame: 8 weeks
Endothelial dysfunction markers
Sush as NOx and ADMA
Time frame: 8 weeks
Hemostatic markers
Such as vWF and thrombomudulin
Time frame: 8 weeks
Muscle strength
Measured by hand grip strength and chair stand test
Time frame: 8 weeks
Whole genome transcriptome analysis in PBMC
Changes in the gene expression profile
Time frame: 8 weeks
Metabolome profile in blood
In blood
Time frame: 8 weeks
Metabolome profile in urine
In urine
Time frame: 8 weeks
No study locations are listed for this record.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oslo Metropolitan University